Skip to main content

Table 1 Demographics, clinical profiles, and neuroimaging data of patients with HFM and HC

From: The cerebellum is associated with 2-year prognosis in patients with high-frequency migraine

 HC
(n = 37)
HFM
(n = 56)
HFM
Good outcome (n = 37)
HFM
Poor outcome (n = 19)
Age39.4 ± 9.340.3 ± 10.540.8 ± 11.139.4 ± 9.6
Sex (F/M)27/1043/1327/1016/3
Aura (%)nil9 (16%)7 (18.9%)2 (10.5%)
Headache frequency-baseline (d/m)nil19.2 ± 7.118.9 ± 7.119.7 ± 7.4
Chronic migrainenil44 (78.6%)29 (78.4%)15 (78.9%)
Disease duration (years)nil17.2 ± 11.315.7 ± 10.220.1 ± 13.0
Headache intensity (NRS 0–10)nil6.5 ± 1.76.6 ± 1.76.3 ± 2.0
MIDASnil43.9 ± 49.020 ± 5062.5 ± 92
HADS-A4.7 ± 2.5#8.9 ± 4.39.1 ± 4.38.5 ± 4.3
HADS-D3.5 ± 2.8#6.8 ± 5.06.7 ± 5.56.8 ± 4.2
Prophylactic drugs usenil48 (85.7%)30 (81.1%)18 (94.7%)
Prophylactic drugs use at 2-year follow-upnil16 (28.6%)10 (27%)6 (31.6%)
Headache frequency at 2-year follow-up (d/m)nil9.0 ± 9.53.3 ± 2.4*20.3 ± 7.8
TIV (mm3)1430.8 ± 129.61399.8 ± 132.51404.7 ± 124.61390.2 ± 149.7
  1. HC healthy controls, HFM high frequency migraine, NRS numeric rating scale, MIDAS Migraine Disability Assessment, HADS-A the anxiety subscale of the Hospital Anxiety and Depression Scale, HADS-D the depression subscale of the Hospital Anxiety and Depression Scale, TIV total intracranial volume
  2. # denotes difference comparing patients with HFM to HC, p < 0.05
  3. *denotes difference comparing patients with HFM with good to poor outcomes, p < 0.05